Latest Hotspot

Zai Lab's new drug Maqituxi Monoclonal Antibody Injection targeting HER2 has been approved in China

3 September 2023
4 min read

On September 1, 2023, the latest announcement on the official website of the NMPA indicates that the Margetuximab injection, applied for by Zai Lab, has been approved for marketing in China. Public information shows that Margetuximab is an Fc-optimized monoclonal antibody acting on HER2, which was introduced by Zai Lab from MacroGenics. The approved indications are for third-line and above treatment of patients with HER2-positive metastatic breast cancer.

Margetuximab, originally researched by MacroGenics, is an Fc-optimized monoclonal antibody targeting Human Epidermal Growth Factor Receptor 2 (HER2). It enhances binding and activation with stimulatory FcγR CD16A and reduces binding with inhibitory FcγR CD32B. This allows it to bind more tightly to effector cells and enhance ADCC effects while retaining anti-tumor proliferative characteristics similar to Trastuzumab. In November 2018, Zai Lab reached a $165 million collaboration with MacroGenics, gaining exclusive rights to develop and commercialize three immunooncology drugs in the Greater China region (including mainland China, Hong Kong, Macau, and Taiwan), one of which is Margetuximab. In vitro data show the optimized Fc domain increases affinity for the activating Fc receptor FCGR3A (CD16A) and decreases affinity for the inhibitory Fc receptor FCGR2B (CD32B). These changes enhance ADCC effects and NK cell activation.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

The launch is based on positive data from the global Phase III SOPHIA study and registration bridging study. The SOPHIA study results show that margetuximab is the only anti-HER2 treatment that has demonstrated improved PFS in head-to-head studies with trastuzumab, highlighting the potential of margetuximab as a critical new treatment option for refractory patients. 

Compared with trastuzumab combined with chemotherapy, margetuximab combined with chemotherapy significantly reduced the risk of disease progression or death in patients, with statistical significance (HR=0.76). The median progression-free survival (mPFS) of the two groups was 5.8 months and 4.9 months, respectively. In terms of the objective remission rate, the rate in the margetuximab combined with chemotherapy group was 22%, higher than the 16% in the control group. Based on this research, the U.S. FDA approved margetuximab for marketing in 2020.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs , indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 应用程序

描述已自动生成

According to the information disclosed by the Synapse database, as of September 2, 2023, there are a total of 507 drugs under investigation targeting HER2, including 150 different indications, involving 531 research institutions, related to 3,317 clinical trials, and as many as 51,590 patents.

In breast cancer patients, many overexpress the human epidermal growth factor receptor 2 (HER2). The HER2 protein promotes the growth of cancer cells, severely affecting the treatment and prognosis of patients; more than 25% of women with metastatic HER2-positive breast cancer will develop brain metastasis. The launch of Margetuximab in China offers a new treatment option for a large number of breast cancer patients.

图形用户界面, 文本, 应用程序

描述已自动生成

Sirnaomics announced positive results from phase 1 clinical trials of siRNA therapy STP707
Latest Hotspot
5 min read
Sirnaomics announced positive results from phase 1 clinical trials of siRNA therapy STP707
3 September 2023
On August 31, 2023, Sirnaomics announced positive results from Phase 1 clinical trials of its RNAi therapy STP707 for treating various solid tumors.
Read →
Neurocrine's VMAT2 inhibitor Valbenazine achieves endpoint in Phase 3 clinical trial
Latest Hotspot
3 min read
Neurocrine's VMAT2 inhibitor Valbenazine achieves endpoint in Phase 3 clinical trial
3 September 2023
Recently, Neurocrine Biosciences announced new data for the VMAT2 inhibitor drug Ingrezza (valbenazine) capsules, including preliminary results from the Phase III KINECT-HD clinical trial.
Read →
SGLT2 Inhibitors - The Cross-Domain Superstar of Antidiabetic Drugs
SGLT2 Inhibitors - The Cross-Domain Superstar of Antidiabetic Drugs
2 September 2023
SGLT2 inhibitors use a unique insulin-independent mechanism to lower blood glucose levels, not only effectively and safely reducing glucose, but also providing significant cardio-renal protection.
Read →
Bristol-Myers Squibb’s mavacamten has announced long-term follow-up data from two phase 3 trials for the treatment of hypertrophic cardiomyopathy
Latest Hotspot
3 min read
Bristol-Myers Squibb’s mavacamten has announced long-term follow-up data from two phase 3 trials for the treatment of hypertrophic cardiomyopathy
2 September 2023
Recently, Bristol Myers Squibb has announced the latest long-term follow-up results of two Phase 3 studies that assessed the treatment efficacy of Camzyos (mavacamten).
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.